



European Patent Office intends to grant BioInvent patent relevant to its F.I.R.S.T.[™] platform

Lund, Sweden – 17 January 2018 – BioInvent International AB (OMXS: BINV) announces today that the European Patent Office, EPO, has communicated its intention to grant the company a patent relevant to its unique, function-based F.I.R.S.T.[™] platform. More precisely, the patent builds on earlier F.I.R.S.T.[™] patents, extending protection to combined use of differential biopanning and high throughput sequencing, such as NGS in identification of antibodies to low expressed cell surface antigens. The European patent should be granted by the EPO once all remaining administrative actions have been completed by BioInvent.

A corresponding patent was recently granted in Australia, and a patent as previously also been granted in Russia. The company has similar patent applications pending in further countries.

Notes to editors:

About BioInvent

BioInvent International AB (OMXS: BINV) is focused on the discovery and development of novel and first-in-class immuno-regulatory antibodies to treat cancer. The Company's clinical programmes are BI-1206, currently in a Phase I/II for non-Hodgkin's lymphoma and chronic lymphatic leukaemia and TB-403, in cooperation with Oncurios, currently in Phase I/II for medulloblastoma. BioInvent has an exciting pre-clinical portfolio based on novel immuno-modulatory antibodies that target regulatory T cells (T-regs) and tumour-associated myeloid cells. In December 2016, the Company signed a strategic research collaboration with Pfizer Inc. BioInvent also works with leading academic institutions including the University of Southampton, Cancer Research UK, and Penn Medicine. BioInvent generates revenues from global partnerships, including Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma and from its manufacturing facility for the production of antibodies for research through to late-stage clinical trials. More information is available at www.bioinvent.se

For further information, please contact:

Björn Frendéus
Acting CEO and Chief Scientific Officer
+46 (0)46 286 25 45
+46 (0)708 11 25 45
bjorn.frendeus@bioinvent.com

BioInvent International AB (publ)

Co. reg. No. 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

This information is information that BioInvent International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.40 a.m. CET, on 17 January, 2018.

